Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-NK-101 + Cetuximab in Advanced CRC and SCCHN
NCT05674526Phase 1Active, not recruiting
- Sponsor
- Wugen
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of WU-NK-101 in colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Wugen. Primary endpoints: Incidence of Adverse Events of WU-NK-101 in combination with cetuximab at 24 months and Maximum Tolerated Dose. Started May 2024; status: active, not recruiting.
02
Drugs
WU-NK-101
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05674526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674526.